Research programme: TRPV1 receptor antagonists - Renovis/Pfizer

Drug Profile

Research programme: TRPV1 receptor antagonists - Renovis/Pfizer

Alternative Names: TRPV1 antagonists - Renovis/Pfizer; Vanilloid receptor antagonists - Renovis/Pfizer

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer; Renovis
  • Developer Evotec AG; Pfizer
  • Class Small molecules
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Pain; Urinary incontinence

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Urinary-incontinence in USA (PO)
  • 27 Mar 2013 Pfizer terminates its collaboration for TRPV1 receptor antagonists in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top